AZ Takes Full Control of Pinetree EGFR Degrader
April 30, 2026
AstraZeneca exercised its option for Pinetree's PTX-299 EGFR degrader, paying $25M and triggering full licence for $500M+ potential value.
April 30, 2026
AstraZeneca exercised its option for Pinetree's PTX-299 EGFR degrader, paying $25M and triggering full licence for $500M+ potential value.